Historical amgn News Stories

Amgen Raises Dividend; Shares Pull Back After High

Amgen (AMGN) boosted its quarterly dividend to $2.52 and reached a 52-week high in early December, but shares retraced after profit-taking. Concrete catalysts include a BMO price-target raise to $372 tied to stronger odds for the MariTide program, a new Los Angeles World Cup partnership, and upcoming investor meetings that could provide near-term clarity.

Amgen Climbs Near 52-Week High; Ventures Spark Now

Amgen shares have traded near their 52-week peak following quiet resilience during a recent sector pullback and renewed investor attention on Amgen Ventures’ participation in a major Series B financing. Concrete recent moves — a small intraday rebound after a one-day drop and a proximity to the November 28 52-week high — suggest the stock is price-sensitive to near-term catalysts such as earnings, pipeline news and partnership activity.

Amgen Q3 Strength: Upgrades, Dividend Pipeline Now

Amgen (AMGN) saw a string of analyst upgrades and raised price targets after a solid Q3 showing: Repatha and Tezspire posted strong growth, free cash flow jumped to $4.2B, and pipeline assets (bemarituzumab, MARITIDE) advanced. Management confirmed a $2.38 Q4 dividend and will present at Citi on Dec. 3. Insider sales were modestly notable. These concrete developments underpin renewed investor confidence while offering specific near-term catalysts.

Amgen Surge: Repatha Data, Q3 Cash Lift AMGN

Amgen rallied after Repatha's primary‑prevention data and solid Q3 results. Strong sales, rising free cash flow, and a dividend boost support AMGN's DJ30 role, while analysts remain measured on upside.

Amgen Repatha Win Sparks Stock Rally; Q3 Beats Now

Amgen’s Q3 beat-and-raise and landmark VESALIUS‑CV results for Repatha drove a sharp AMGN rally. The clinical win in primary prevention and stronger guidance lifted investor sentiment, prompting technical breakouts and mixed analyst reactions.

Amgen Unveils $600M Research Hub; Stock Dips

Amgen announced a $600 million research and innovation hub in Thousand Oaks this week, prompting a modest near‑term pullback in AMGN shares. The investment signals a long‑term R&D commitment while investors weigh short‑term capital spending and upcoming earnings.